- Home
- IMCR vs PTGX Comparison
IMCR vs PTGX Comparison
Compare IMCR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PTGX
- Stock Information
- Founded
- IMCR 2008
- PTGX 2006
- Country
- IMCR United Kingdom
- PTGX United States
- Employees
- IMCR N/A
- PTGX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- PTGX Health Care
- Exchange
- IMCR Nasdaq
- PTGX Nasdaq
- Market Cap
- IMCR 1.7B
- PTGX 3.3B
- IPO Year
- IMCR 2021
- PTGX 2016
- Fundamental
- Price
- IMCR $36.22
- PTGX $55.48
- Analyst Decision
- IMCR Buy
- PTGX Strong Buy
- Analyst Count
- IMCR 10
- PTGX 9
- Target Price
- IMCR $58.13
- PTGX $67.11
- AVG Volume (30 Days)
- IMCR 286.3K
- PTGX 856.6K
- Earning Date
- IMCR 08-07-2025
- PTGX 08-05-2025
- Dividend Yield
- IMCR N/A
- PTGX N/A
- EPS Growth
- IMCR N/A
- PTGX N/A
- EPS
- IMCR N/A
- PTGX 0.86
- Revenue
- IMCR $333,581,000.00
- PTGX $207,801,000.00
- Revenue This Year
- IMCR $26.82
- PTGX N/A
- Revenue Next Year
- IMCR $8.15
- PTGX $53.09
- P/E Ratio
- IMCR N/A
- PTGX $64.15
- Revenue Growth
- IMCR 25.75
- PTGX N/A
- 52 Week Low
- IMCR $23.15
- PTGX $32.50
- 52 Week High
- IMCR $40.88
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- IMCR 64.59
- PTGX 59.24
- Support Level
- IMCR $32.20
- PTGX $49.38
- Resistance Level
- IMCR $36.36
- PTGX $57.73
- Average True Range (ATR)
- IMCR 1.18
- PTGX 2.06
- MACD
- IMCR 0.33
- PTGX 0.25
- Stochastic Oscillator
- IMCR 96.88
- PTGX 73.09
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.